Cereno Scientific AB (publ) (STO:CRNO.B)

Sweden flag Sweden · Delayed Price · Currency is SEK
8.04
+0.23 (3.01%)
At close: Dec 3, 2025
31.80%
Market Cap 2.44B
Revenue (ttm) 46.66M
Net Income (ttm) -113.29M
Shares Out 295.32M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,100,518
Average Volume 800,627
Open 7.50
Previous Close 7.81
Day's Range 7.49 - 8.18
52-Week Range 4.70 - 11.90
Beta -0.04
RSI 57.70
Earnings Date Nov 27, 2025

About Cereno Scientific AB

Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden and internationally. The company’s lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and anti-thrombotic properties. Its drugs portfolio ... [Read more]

Sector Healthcare
Founded 2012
Employees 10
Stock Exchange Nasdaq Stockholm
Ticker Symbol CRNO.B
Full Company Profile

Financial Performance

In 2024, Cereno Scientific AB's revenue was 80.90 million, an increase of 64.18% compared to the previous year's 49.28 million. Losses were -99.53 million, 106.9% more than in 2023.

Financial Statements

News

There is no news available yet.